|
Understanding the origin and pathogenesis of epithelial ovarian cancer
|
1F32CA159523-01
|
$53,042
|
Kim, Jaeyeon
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-05S1
|
$75,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-05
|
$2,934,758
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Role of the BMP SMADs in Oncogenesis
|
5R01CA138628-02
|
$354,370
|
Pangas, Stephanie
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
2U10CA035192-27A1
|
$569,700
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Analysis of BRCA1 recombination functions
|
5R01CA095175-08
|
$295,223
|
SCULLY, RALPH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
5R01CA129339-04
|
$342,168
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Utrasensitive bioassays using palladium catalyzed chemical amplification
|
1R43CA159478-01
|
$199,996
|
Lelental, Mark
|
BIOFORMATIX, INC.
|
|
A Novel Nanocoaxial Biosensor for Detection of Cancer Biomarkers
|
5R21CA137681-02
|
$211,697
|
CHILES, THOMAS
|
BOSTON COLLEGE
|
|
Women's Health Study: Continued Follow-up
|
5R01CA047988-20
|
$1,808,081
|
BURING, JULIE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Biochemical Markers in the Nurses? Health Study Cohort
|
5U01CA049449-22
|
$1,115,005
|
Hankinson, Susan
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Targeting lipid metabolic and signaling enzyme in ovarian cancer
|
5R21CA150237-02
|
$230,673
|
NG, SHU-WING
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways
|
5R01CA135242-02
|
$358,689
|
Sengupta, Shiladitya
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Dietary and Hormonal Determinants of Cancer in Women
|
5P01CA087969-12
|
$4,914,636
|
Stampfer, Meir
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Characteristics of tubal ligation and risk of epithelial ovarian cancer
|
1R03CA143918-01A1
|
$101,020
|
Tworoger, Shelley
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-02
|
$188,304
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Proteo-genomic Discovery, Prioritization and Verification of Cancer Biomarkers
|
1U24CA160034-01
|
$3,034,910
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
Nanosystems Biology Cancer Center 2
|
5U54CA151819-02
|
$2,446,327
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Phase II SBIR Topic 262 "Patient-Centered Communication for Post-Diagnosis Care"
|
N44CO110107-000
|
$749,985
|
YANG, DERSHUNG
|
CARACAL INC
|
|
Carle Cancer Center Community Clinical Oncology Program
|
5U10CA035195-28
|
$794,063
|
ROWLAND, KENDRITH
|
CARLE FOUNDATION
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
5U01CA062502-18
|
$746,424
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cytogenetic and Molecular Studies of Chromosome 22
|
5R01CA039926-23
|
$366,215
|
EMANUEL, BEVERLY
|
CHILDRENS HOSPITAL OF PHILADELPHIA
|
|
Delaware/Christiana Care CCOP
|
5U10CA045418-25
|
$1,147,220
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Research and Mentoring on Energetic Factors and Cancer: Established Investigator
|
5K05CA136967-03
|
$139,569
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Breast and Other Cancers in the California Teachers Cohort
|
5R01CA077398-13
|
$2,524,331
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-28S1
|
$91,911
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-28S2
|
$75,000
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-28S3
|
$139,999
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-28
|
$2,225,352
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-24
|
$349,765
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Transforming growth factor beta signaling pathways
|
5R01CA055536-20
|
$195,663
|
HOWE, PHILIP
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
CCOP: Colorado Cancer Research Program
|
5U10CA067753-16
|
$1,008,553
|
Pajon, Eduardo
|
COLORADO CANCER RESEARCH PROGRAM, INC.
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-15
|
$237,949
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY-FORT COLLINS
|
|
Functional Outcomes of Cdk6 and Eya2 Interaction
|
2R15CA125731-02A1
|
$419,375
|
Grossel, Martha
|
CONNECTICUT COLLEGE
|
|
Academic-industrial partnership for development of in vivo imaging systems and me
|
3R01CA133148-04S1
|
$56,254
|
XU, CHRIS
|
CORNELL UNIVERSITY ITHACA
|
|
Academic-industrial partnership for development of in vivo imaging systems and me
|
5R01CA133148-04
|
$343,818
|
XU, CHRIS
|
CORNELL UNIVERSITY ITHACA
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S5
|
$11,164,583
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
CANCER CENTER SUPPORT GRANT
|
3P30CA006516-46S6
|
$75,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INSTITUTE
|
|
The High Cost of Risk Reduction: Addressing Sexual Dysfunction after Oophorectomy
|
1R03CA153815-01A1
|
$87,500
|
Bober, Sharon
|
DANA-FARBER CANCER INSTITUTE
|
|
BRCA1 Function in Post-Damage Nuclear Foci
|
5R01CA136512-03
|
$511,671
|
LIVINGSTON, DAVID
|
DANA-FARBER CANCER INSTITUTE
|
|
Dartmouth Center for Cancer Nanotechnology Excellence
|
5U54CA151662-02
|
$2,415,438
|
Baker, Ian
|
DARTMOUTH COLLEGE
|
|
Cancer Center Support Grant
|
5P30CA023108-33
|
$3,125,750
|
ISRAEL, MARK
|
DARTMOUTH COLLEGE
|
|
Chimeric NKG2D receptors in ovarian cancer immunotherapy
|
5R01CA130911-04
|
$321,839
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
5U10CA045807-26
|
$1,251,900
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Role of TbRIII in Regulating Motility and Invasion
|
5R01CA135006-03
|
$425,769
|
BLOBE, GERARD
|
DUKE UNIVERSITY
|
|
Adherence to Cancer Risk Management Among Unaffected BRCA1/2Mutation Carriers
|
1R03CA157212-01A1
|
$84,838
|
Buchanan, Adam
|
DUKE UNIVERSITY
|
|
Duke Comp Cancer Inst. Core Support Grant
|
3P30CA014236-37S1
|
$37,988
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Duke Comp Cancer Inst. Core Support Grant
|
5P30CA014236-37
|
$5,723,821
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Atlantic Breast and Gynecologic Clinical Validation Center
|
5U01CA084955-12
|
$498,270
|
Marks, Jeffrey
|
DUKE UNIVERSITY
|
|
Duke Comp Cancer Inst. Core Support Grant
|
3P30CA014236-37S2
|
$75,000
|
MEANS, ANTHONY
|
DUKE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|